Nachrichten zur GSK PLC LS-,3125 Aktie

GSK 100% backs London listing, says boss

GSK PLC (LSE:GSK, NYSE:GSK) has issued its support to the flagging London market, stating that it is “unequivocally, 100 per cent…

GSK still appealing despite US legal setback says broker

GSK PLC (LSE:GSK, NYSE:GSK) is still appealing - even in the wake of a significant legal setback, according to regional…

GSK appeals Delaware Zantac ruling

GSK PLC (LSE:GSK, NYSE:GSK) and other pharmaceutical companies asked a Delaware court to allow an appeal of a ruling permitting…

GSK RSV jab receives label expansion from US regulator

GSK PLC (LSE:GSK, NYSE:GSK) has confirmed that the US Food & Drug Administration has approved Arexvy for preventing respiratory syncytial…

GSK: Still reasons to be cheerful rather than fearful after nightmare Monday

What was supposed to be a stellar day for GSK PLC (LSE:GSK, NYSE:GSK) at the annual American Society of Clinical…

GSK-Aktie stürzt nach Gerichtsurteil ab - Aktienanalyse

Wien (www.aktiencheck.de) - GSK-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt die…

GSK: Zantac-Klagen - Belastungen in Milliardenhöhe? Aktienanalyse

Kulmbach (www.aktiencheck.de) - GSK-Aktienanalyse von "Der Aktionär": Marion Schlegel vom Anlegermagazin "Der Aktionär" nimmt die Aktie von GSK plc (ISIN: GB00BN7SWP63,…

GSK: Zantac litigation obscures the positives, says leading investment bank

Deutsche Bank has maintained its "buy" rating on GSK PLC (LSE:GSK, NYSE:GSK) despite the recent setback in the Zantac litigation as…

GSK: Zantac litigation obscures the positives, says leading investment bank

Deutsche Bank has maintained its "buy" rating on GSK PLC (LSE:GSK, NYSE:GSK) despite the recent setback in the Zantac litigation as…

GSK shares plunge after US judge rules Zantac cases can go to trial

GSK PLC (LSE:GSK, NYSE:GSK) lost over £6 billion in market value after court judge in the US state of Delaware allowed more…

GSK to appeal US judges Zantac ruling, shares plunge

GSK PLC (LSE:GSK, NYSE:GSK) lost over £6 billion in market value after court judge in the US state of Delaware allowed more…

GSK shares plunge after US judge rules Zantac cases can go ahead

GSK PLC (LSE:GSK, NYSE:GSK) lost over £6 billion in market value after court judge in the US state of Delaware allowed more…

GSK to appeal US judges Zantac ruling

GSK PLC (LSE:GSK, NYSE:GSK) says it disagrees with a decision by a court judge in the US state of Delaware who…

GSK shares plunge after US judge rules Zantac cases can go to trial

GSK PLC (LSE:GSK, NYSE:GSK) lost over £6 billion in market value after court judge in the US state of Delaware allowed more…

GSK plc: Long-Term Cash Cow

…

GSK found not guilty in Zantac trial

British pharmaceuticals big cap GSK PLC (LSE:GSK, NYSE:GSK) has won a high-stake personal injury case in the state of Illinois,…

GSK found not guilty in Zantac trial

British pharmaceuticals big cap GSK PLC (LSE:GSK, NYSE:GSK) has won a high-stake personal injury case in the state of Illinois,…

GSK: Zantac settlement could reach $2bn, says investment bank

GSK PLC (LSE:GSK, NYSE:GSK) may face a settlement of up to $2 billion to resolve thousands of lawsuits related to…

GSK: Moderate Bewertung trotz Kursanstieg - Aktienanalyse

Wien (www.aktiencheck.de) - GSK-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), stuft die…

GSK confirms Haleon exit for total of £3.9 billion

GSK PLC (LSE:GSK, NYSE:GSK) confirmed it has raised a total of £3.9 billion through the exit of its stake in…

GSK confirms exit of Haleon stake for £3.9 billion

GSK PLC (LSE:GSK, NYSE:GSK) confirmed it has raised a total of £3.9 billion through the exit of its stake in…

GSK plc (GSK) Q1 2024 Earnings Call Transcript

…

GSK beginning to alleviate long-held concerns, say analysts

GSK PLC (LSE:GSK, NYSE:GSK) is approaching 18-month highs after the pharma groups boss Emma Walmsley raised the full-year outlook on the…

Pharmahersteller GSK erhöht Gewinnziel für 2024

LONDON (dpa-AFX) - Der Pharmakonzern GSK ist besser als erwartet in das neue Jahr gestartet.…

GSK Q1 beats consensus and FY numbers upgraded after vaccines boost

GSK PLC (LSE:GSK, NYSE:GSK) has confirmed what recent prescription data hinted at: Its vaccines business is firing on all cylinders.…

The Global Market for HPV Associated Disorders, 2018-2023 and 2024-2033, Featuring Profiles of Leading Players AstraZeneca, Roche, Biocon, GlaxoSmithKline, and Merck & Co

Dublin, April 19, 2024 (GLOBE NEWSWIRE) -- The "HPV Associated Disorders Global Market Report 2024" report has been…

Global CAR T-Cell Therapy Market Size To Worth USD 21.92 Billion By 2033 | CAGR of 17.72%

The Global CAR T-Cell Therapy Market Size was Valued at USD 4.29 Billion in 2023 and the Worldwide CAR T-Cell…

GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US

GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the…

ANALYSE-FLASH: Jefferies belässt GSK auf 'Buy' - Ziel 1950 Pence

NEW YORK (dpa-AFX Broker) - Das Analysehaus Jefferies hat die Einstufung für GSK auf "Buy"…

GSK plc (GSK) TD Cowen 44th Annual Health Care Conference (Transcript)

…

GSK: Has Blenreps blockbuster status been restored?

GSK PLC (LSE:GSK, NYSE:GSK) cancer discovery Blenreps blockbuster potential has been reawakened, according to Shore Capital. The broker was commenting...…

GSK boss sees pay jump 51% in 2023

GSK PLC (LSE:GSK, NYSE:GSK) boss Emma Walmsley saw her overall pay rise 51% to around £13 million in 2023 after…

GSK settles another Zantac lawsuit in California

GSK PLC (LSE:GSK, NYSE:GSK) has confidentially settled a lawsuit in California that claimed its now-discontinued heartburn medication, Zantac, caused...…

GSK settles another California lawsuit

GSK PLC (LSE:GSK, NYSE:GSK) has confidentially settled a lawsuit in California that claimed its now-discontinued heartburn medication, Zantac, caused...…

Antisense and RNAi Therapeutics Market Size & Share Envisaged To Reach USD 18.43 Billion By 2032, at 17.8% CAGR Growth: Polaris Market Research

The global Antisense and RNAi Therapeutics Market size and share is currently valued at USD 4.34 billion in 2023. It…

dpa-AFX ProFeed